Search results
Results from the WOW.Com Content Network
The stock of Thermo Fisher Scientific (NYSE:TMO, 30-year Financials) is estimated to be fairly valued, according to GuruFocus Value calculation.
Thermo Fisher forecast annual revenue in a range of $42.1 billion to $43.3 billion, shy of analysts' expectations of $42.93 billion at midpoint, according to LSEG data.
For example, Citi, Goldman Sachs, J.P. Morgan, and Morgan Stanley all forecast the S&P 500 will rise nearly 10% this year to 6,500, a little below other outlooks. However, Citi thinks the momentum ...
The Waltham, Massachusetts-based firm said it now expects annual adjusted profit of $21.14 to $22.02 per share, compared with its previous forecast of $20.95 to $22 per share.
In 2021, Thermo Fisher announced the construction of a cell therapy development, manufacturing and collaboration center in cooperation with University of California, San Francisco on the school's Mission Bay campus. [81] In February 2022, Thermo Fisher Scientific announced a 15-year strategic collaboration agreement with Moderna, Inc.
With the fourth-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the ...
Today's Research Daily features new research reports on 16 major stocks, including PepsiCo, Inc. (PEP), Thermo Fisher Scientific Inc. (TMO) and Canadian National Railway Company (CNI).
The stock of Thermo Fisher Scientific (NYSE:TMO, 30-year Financials) is believed to be modestly overvalued, according to GuruFocus Value calculation.